Summary Renal function was determined before and at varying times after chemotherapy in 62 patients with metastatic germ cell tumours treated with carboplatin. Eighteen patients were excluded because of urinary tract obstruction, leaving 44 evaluable patients treated with carboplatin either as a single agent (13 patients) or in combination with other agents (31 patients). No significant differences were observed in mean"Cr-labelled Ethylenediamine tetraacetic acid (EDTA) clearances before and after carboplatin in either the group as a whole (P = 0.58), or when assessment at 1 month or less (P = 0.4), 3 months or less (P = 0.91), or later than 3 months (P = 0.38) were analysed. Carboplatin does not have significant renal toxicity when used at conventional dosage in patients with germ cell tumours.
The nephrotoxicity of cisplatin in the treatment of various malignancies, including testicular germ cell tumours, is well documented (Dentino et al., 1978; Meijer et al., 1983; Groth et al., 1986; Hansen et al., 1988; Barton et al., 1988; Hamilton et al., 1989) . With the introduction of the cisplatin analogue carboplatin it was hoped that an equally effective treatment might be available without the attendant nephrotoxicity, obviating the hospitalisation, intensive hydration and forced diuresis needed for cisplatin therapy (Calvert et al., 1985) .
A recent study of 10 patients with lung cancer treated with carboplatin and vincristine at conventional doses showed a median fall in glomerular filtration rate (GFR) of 19% post treatment (Sleijfer et al., 1989) (GFR + 25) to result in an area under the serum concentration/time curve of 5 mg min ml-' (Calvert et al., 1985) . In all patients the dose was reviewed after the day 16 full blood count. In patients with a nadir white cell count above 2,000 mm-2 or a platelet count above 100,000 mm-3 the dose was increased by 10%. In patients with a nadir white cell count below 1,000 mm 3 or a platelet count below 50,000 mm-3 the dose was reduced by 10% (Horwich et al., 1991) .
Glomerular filtration rate (GFR) was estimated from the plasma decay curve of 51-Cr-EDTA as previously described (Chantler et al., 1969) , and was not corrected for body surface area. All patients had their GFR measured before treatment, and this was repeated between 2 weeks and 26 months following their last injection of carboplatin. The post-chemotherapy assessment was performed at 1 month or less in 16 patients, 1-3 months in six patients, and more than 3 months after the last dose of carboplatin in 22 patients.
Statistical analysis of pre-and post-chemotherapy GFRs was performed using a paired t-test.
Results
The mean carboplatin doses received by the 44 evaluable patients were 757.3 mg in those treated with single agent carboplatin (range 485-950 mg), and 739.4 mg in those treated with CEB (range 480-1,000mg).
The mean pre-treatment GFR in the 44 evaluable patients was 124.4mlmin-'. In the group of patients assessed at 1 month or less the mean pre-tratment GFR was 116.3 ml min-' (range 72-181 ml min-'). When the six patients assessed at 1-3 months were added to these the mean pretreatment GFR was 118.4 ml min-' (range 72-181 ml min-'). In the group of patients assessed more than 3 months after carboplatin the mean pre-treatment GFR was 130.4 ml min-' (range 87-205 ml min-'). The percentage change in GFR in the 44 analysed patients is shown in relation to the timing of their post-chemotherapy assessment in Figure 1 . It is estimated that the individual accuracy for serial estimations of GFR by this method will be within 10%, and it is apparent that most patients experienced no significant change or an improvement in renal function following treatment with carboplatin. Using paired t-test analyses, the mean GFRs post-treatment were not significantly different from pre-treatment values when postchemotherapy assessments were analysed at 1 month or less (P = 0.4), 3 months or less (P = 0.91), greater than 3 months (P = 0.38), or when all evaluable patients were considered (P = 0.58) ( Table I) .
When the whole group of 62 patients was examined, 13 (21%) were shown to have experienced a fall in GFR of 10% six had had hydronephrosis which improved or resolved after treatment (two patients having had a stent inserted), and three had evidence of displacement of the renal tract without hydronephrosis which improved after treatment. It is possible that resolution of these factors after carboplatin might have contributed to the improvement seen in GFR. No contributory factors could be identified in ten patients.
Discussion
Given the success of treatment with chemotherapy in metastatic germ cell tumours, the problem of toxicity is one of major importance. Carboplatin was developed as a cisplatin analogue whose spectrum of toxicity differed from the parent compound in being less nephrotoxic, neurotoxic, and ototoxic, though more toxic to bone marrow. It is important to know whether substitution of cisplatin by carboplatin actually does reduce the renal damage previously reported in testicular tumour patients (Dentino et al., 1978; Meijer et al., 1983; Groth et al., 1986; Hansen et al., 1988; Hamilton et al., 1989) . It is also important to know whether carboplatin might substitute for cisplatin in patients unsuitable for treatment with the latter by virtue of poor renal function. Sleijfer et al. (1989) reported on renal function in ten patients with lung cancer treated with carboplatin and vincristine, and suggested that carboplatin caused a significant fall in GFR that was detectable after the second course of chemotherapy. The dose of carboplatin was 400 mg m-2, repeated every 4 weeks to a maximum of five cycles. The age range of their patients was 48 to 69 years, which is considerably older than the age range in this series of testicular tumour patients.
In the phase I studies of carboplatin no evidence of nephrotoxicity attributable to the drug was seen, even in patients with impaired renal function, at doses ranging between 150 and 520 mg m2 (Egorin et al., 1984; Calvert et al., 1985) . However, in phase I studies of high dose carboplatin there is evidence of some reduction in the post treatment GFR (Gore et al., 1987; Shea et al., 1989) , although this may be a transient phenomenon which usually recovers by 3 months after chemotherapy (Hardy et al., 1990) . In this study using conventional doses of carboplatin we have found no overall evidence of a similar, early reduction in GFR, patients being as likely to experience an improvement in their GFR as they are a decline in the period of up to 1 month carboplatin ( Figure 1 , Table I ). Carboplatin has been shown to be nephrotoxic in rats, but only in combination with the aminoglycoside tobramycin, and not when used alone (Bregman & Williams, 1986) . We have found no overall evidence of significant nephrotoxicity in patients with metastatic germ cell tumours at any time after treatment with carboplatin. However, of the whole group of 62 patients (including those patients not analysed statistically) 21% had a 10% or greater fall in their post treatment GFR. In half of these patients other significant contributary factors were present, but there remain a small number of patients with a decline in their post-chemotherapy GFR in whom it is difficult to exclude the possibility that the chemotherapy could have been responsible. It is difficult to assess the extent to which factors such as the state of hydration, concomitant alcohol consumption, nausea and vomiting, and intercurrent illness may affect day-to-day variations in GFR in these patients. Such physiological variations in GFR could be contributary in those patients shown in Figure  I to have had large percentage changes in post-chemotherapy GFR, in whom there was no evidence of hydronephrosis or encroachment on the urinary tract by disease.
On the basis of these results we conclude that carboplatin is a safe drug to administer without intravenous hydration, and that it does not cause a significant degree of nephrotoxicity in patients with metastatic germ cell tumours.
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